Clinical Trials · NCT05597202
Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
- Phase
- Phase 4
- Recruitment status
- Unknown
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Enrollment
- 22
- Start date
- Jan 2023
- Locations
- 1 site, Netherlands
- Primary endpoint
- Difference in coronary 68Ga-Dotatate uptake after treatment.